Literature DB >> 22765994

Substance P is an early mediator of peritoneal fibrinolytic pathway genes and promotes intra-abdominal adhesion formation.

Anthony J Esposito1, Stanley J Heydrick, Michael R Cassidy, Joseph Gallant, Arthur F Stucchi, James M Becker.   

Abstract

BACKGROUND: The substance P (SP) or neurokinin-1 receptor pathway has been implicated in intra-abdominal adhesion formation, in large part through its effects on peritoneal fibrinolysis. This study investigates the role of SP as an early mediator of the messenger RNA (mRNA) expression of key components of the peritoneal fibrinolytic system and other fundamental adhesiogenic pathways.
MATERIALS AND METHODS: Intra-abdominal adhesions were surgically induced in 28 rats using the ischemic button model. mRNA levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1), hypoxia-inducible factors (HIFs) 1α and 2α, and vascular endothelial growth factor A (VEGF-A) were measured in adhesive button tissue taken at time 0 and 1, 3, 6, 12, and 24h after surgery in rats receiving an intraoperative peritoneal bolus (25mg/kg) of a neurokinin-1 receptor antagonist (NK-1RA) or saline. Peritoneal fluid fibrinolytic activity was measured in peritoneal lavages taken at the same time points.
RESULTS: SP levels increased (P≤0.05) within 1h postoperatively followed by an increase (P≤0.05) in tPA mRNA expression from 3 to 6h after surgery along with a striking increase (P≤0.05) in PAI-1 mRNA expression from 3 to 12h. NK-1RA administration further increased (P≤0.05) tPA mRNA expression and significantly blunted the increase in PAI-1 mRNA levels. The NK-1RA increased (P≤0.05) fitbrinolytic activity in peritoneal fluid at 3, 12, and 24h after surgery. HIF-1α and VEGF-A mRNA expressions increased from 3 to 12h (P≤0.05) and from 1 to 3h (P≤0.05) after surgery, respectively, whereas HIF-2α mRNA expression steadily decreased. NK-1RA delayed the rise in HIF-1α mRNA and ablated the changes in HIF-2α and VEGF-A mRNAs.
CONCLUSIONS: SP is a pleiotropic early regulator of mRNA levels of key adhesiogenic mediators after surgery, suggesting that it may be a viable therapeutic target.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22765994     DOI: 10.1016/j.jss.2012.05.056

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Combined intraoperative administration of a histone deacetylase inhibitor and a neurokinin-1 receptor antagonist synergistically reduces intra-abdominal adhesion formation in a rat model.

Authors:  Michael R Cassidy; Alan C Sherburne; Stanley J Heydrick; Arthur F Stucchi
Journal:  Surgery       Date:  2015-03       Impact factor: 3.982

2.  Blocking substance P signaling reduces musculotendinous and dermal fibrosis and sensorimotor declines in a rat model of overuse injury.

Authors:  M F Barbe; B A Hilliard; P W Fisher; A R White; S P Delany; V J Iannarone; M Y Harris; M Amin; G E Cruz; S N Popoff
Journal:  Connect Tissue Res       Date:  2019-08-23       Impact factor: 3.417

Review 3.  Substance P, A Promising Therapeutic Target in Musculoskeletal Disorders.

Authors:  Kyung Rae Ko; Hyunil Lee; Soo-Hong Han; Wooyeol Ahn; Do Kyung Kim; Il-Su Kim; Bo Sung Jung; Soonchul Lee
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

4.  Novel thermosensitive hydrogel for preventing formation of abdominal adhesions.

Authors:  Xiang Gao; Xiaohui Deng; Xiawei Wei; Huashan Shi; Fengtian Wang; Tinghong Ye; Bin Shao; Wen Nie; Yuli Li; Min Luo; Changyang Gong; Ning Huang
Journal:  Int J Nanomedicine       Date:  2013-07-11

5.  Peritoneal adhesion prevention with a biodegradable and injectable N,O-carboxymethyl chitosan-aldehyde hyaluronic acid hydrogel in a rat repeated-injury model.

Authors:  Linjiang Song; Ling Li; Tao He; Ning Wang; Suleixin Yang; Xi Yang; Yan Zeng; Wenli Zhang; Li Yang; Qinjie Wu; Changyang Gong
Journal:  Sci Rep       Date:  2016-11-21       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.